The headache-inducing effects of cilostazol in men and women with migraine without aura
Key facts
- Where
- Odense M, DániaSee the site
- Phase
- 1/2. fázis
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Dánia
- Syddansk Universitet (University of Southern Denmark)Odense M, DániaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Syddansk Universitet (University of Southern Denmark)
- Trial code
- EU 2025-521520-29-00
- Record updated
- 2025. június 20.
- Original description
The main objective of this study is to investigate the role of the intracellular messenger cAMP in migraine by exploring potential sex-related differences in the response to cilostazol in individuals with migraine.Read full original descriptionShow less
The main objective of this study is to investigate the role of the intracellular messenger cAMP in migraine by exploring potential sex-related differences in the response to cilostazol in individuals with migraine.
Inclusion: Healthy men and women with a diagnosis of episodic migraine without aura according to the International Classification; Age: 18-65 years; Weight: 50-100 kg; Safe contraception (including hormonal therapies, intrauterine devices and/or oral pills) for women during the entire period of the study; Fluency in Danish or English.
Exclusion: Use of concomitant medications that have changed in dosage within 14 days prior to screening or are expected to change during the study period; Concomitant use of anticoagulants, antiaggregants and drugs that inhibit CYP3A4 and CYP2C19 activity; Assumption of analgesic medications in the 24 hours preceding the experimental days; History or clinical signs of cardiovascular disease, cardiac arrhythmia, unstable angina pectoris, impaired liver function and/or kidney function; Recent history of myocardial infarction or major cardiac surgery; Anamnestic or clinical signs of mental illness, abuse or smoking; Anamnestic or clinical signs of diseases of any kind considered by the investigating physician relevant for participation in the study; Known allergy to any component of cilostazol “Aliud”; Hypertension (> 150/100 mmHg) or hypotension (< 90/50 mmHg) at the Screening Visit; Any other type of headache (excluding < 3 days of tension-type headache per month), according to the International Classification; Positive pregnancy test at the Screening and/or before the start of the experiment; Member of investigational site staff or relative of investigators; Headache less than 24 hours before the start of the experiment; Drinking coffee, cola or alcohol less than 8 hours before the start of the experiment.